Securities Fraud Investigations Launched into Fulcrum Therapeutics and Shake Shack

Key Facts

1Levi & Korsinsky initiated a securities fraud investigation into Fulcrum Therapeutics after its stock fell 50% following FDA safety concerns regarding PRC2 inhibition.

2Shake Shack is facing a legal probe after abruptly cutting its Q2 2026 same-store sales growth projections from 3-5% to 2.5-3%.

Amid rising legal scrutiny over corporate transparency, Levi & Korsinsky has initiated securities fraud investigations into Fulcrum Therapeutics and Shake Shack following significant negative catalysts. Fulcrum Therapeutics saw its stock plummet 50% after the FDA raised safety concerns regarding its PRC2 inhibition drug program. Simultaneously, Shake Shack is under investigation after abruptly slashing its Q2 2026 same-store sales growth projections to 2.5-3%, down from the previously guided range of 3-5%.

These probes emerge as both the biotech and consumer sectors face heightened volatility. While peers like Chipotle (CMG) have maintained more consistent guidance, Shake Shack’s sudden revision has triggered concerns over internal forecasting accuracy, per market data. In the biotech space, regulatory setbacks from the FDA often lead to class-action solicitations, especially when clinical safety issues result in a massive loss of shareholder value within a single trading session.

Investors should closely watch current price levels, with FULC closing at $3.55 and SHAK at $58.33 (close June 11, 2026). While the upcoming economic calendar shows no immediate corporate catalysts for either firm in the next week, the progression of these legal inquiries remains a primary risk factor. Future updates from the FDA regarding Fulcrum’s safety protocols and Shake Shack’s actual Q2 earnings results will be critical for determining long-term sentiment.